Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): Case report and the focused review of the literature

View through CrossRef
Background: The introduction of newly formulated extended release (ER) morphine with sequestered naltrexone (Embeda) has provided another treatment option for moderate to severe persistent pain. Embeda was designed to be an abuse-deterrent opioid formulation. Naltrexone is a centrally acting opioid receptor antagonist that blocks the action of opioid. When taken as directed, insignificant amount of sequestered naltrexone would reach systemic circulation, but upon tampering, the released naltrexone may blunt the euphoria of opioids, and possibly precipitate opioid withdrawal in opioid-dependent patient.Objective: To describe a case report of a 50-year-old opioid-dependent male who developed acute opioid withdrawal after taking crushed Embeda.Case report: A 50-year-old male with severe, chronic low back pain due to degenerative disc disease was referred to our clinic for pain management. He was taking ER oxycodone 80 mg tid and Roxicodone 30 mg qid prn, with inadequate pain relief. A trial of ER oxymorphone was decided, at 40 mg 1-2 doses bid. The patient returned to the clinic 1 week early, out of his ER oxymorphone. At this time, the decision to switch him to Embeda was made, at 80 mg/3.2 mg, 1-2 doses bid. The patient and his family members were counseled about risk involved with tampering with Embeda. A few hours later, our clinic was informed that the patient was brought to emergency room by ambulance, in severe opioid withdrawal. He was treated with IV fluid, antiemetics, clonidine, and IV hydromorphone. His condition improved and he was discharged home the next morning. Later on, the patient admitted that he took two prescribed Embeda within half an hour, the 1st one whole and the 2nd one crushed. He further admitted that he did so against our medical advice.Conclusion: Taking tampered Embeda may precipitate opioid withdrawal in opioid-tolerant patient. To the best of our knowledge, this is the first report of induced opioid withdrawal following consumption of crushed Embeda.
Title: Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): Case report and the focused review of the literature
Description:
Background: The introduction of newly formulated extended release (ER) morphine with sequestered naltrexone (Embeda) has provided another treatment option for moderate to severe persistent pain.
Embeda was designed to be an abuse-deterrent opioid formulation.
Naltrexone is a centrally acting opioid receptor antagonist that blocks the action of opioid.
When taken as directed, insignificant amount of sequestered naltrexone would reach systemic circulation, but upon tampering, the released naltrexone may blunt the euphoria of opioids, and possibly precipitate opioid withdrawal in opioid-dependent patient.
Objective: To describe a case report of a 50-year-old opioid-dependent male who developed acute opioid withdrawal after taking crushed Embeda.
Case report: A 50-year-old male with severe, chronic low back pain due to degenerative disc disease was referred to our clinic for pain management.
He was taking ER oxycodone 80 mg tid and Roxicodone 30 mg qid prn, with inadequate pain relief.
A trial of ER oxymorphone was decided, at 40 mg 1-2 doses bid.
The patient returned to the clinic 1 week early, out of his ER oxymorphone.
At this time, the decision to switch him to Embeda was made, at 80 mg/3.
2 mg, 1-2 doses bid.
The patient and his family members were counseled about risk involved with tampering with Embeda.
A few hours later, our clinic was informed that the patient was brought to emergency room by ambulance, in severe opioid withdrawal.
He was treated with IV fluid, antiemetics, clonidine, and IV hydromorphone.
His condition improved and he was discharged home the next morning.
Later on, the patient admitted that he took two prescribed Embeda within half an hour, the 1st one whole and the 2nd one crushed.
He further admitted that he did so against our medical advice.
Conclusion: Taking tampered Embeda may precipitate opioid withdrawal in opioid-tolerant patient.
To the best of our knowledge, this is the first report of induced opioid withdrawal following consumption of crushed Embeda.

Related Results

Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct Introduction Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical activi...
Use of Naltrexone for Patients With Stimulant Use Disorder in Malaysia: Protocol for a Retrospective Cohort Study
Use of Naltrexone for Patients With Stimulant Use Disorder in Malaysia: Protocol for a Retrospective Cohort Study
Background Naltrexone is an opioid receptor antagonist. Naltrexone is used to block the euphoric and sedative effects of drugs such as heroin, codeine, and morp...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract Introduction Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
NMDA antagonists and clonidine block c‐fos expression during morphine withdrawal
NMDA antagonists and clonidine block c‐fos expression during morphine withdrawal
AbstractThe c‐fos gene is expressed in the central nervous system (CNS) in response to neuronal stimuli. Induction of c‐fos in certain CNS regions occurs following naltrexone preci...
Targeting the neuropeptide Y system in the locus coeruleus
Targeting the neuropeptide Y system in the locus coeruleus
Neuropeptide Y (NPY), a neurochemical mediator of stress resilience, may possess therapeutic efficacy in stress-induced opioid abuse and relapse. The locus coeruleus (LC)-noradrene...

Back to Top